Delisting risk
Cardiff Oncology (CRDF)
Develops onvansertib for first-line RAS-mutated metastatic colorectal cancer.
$1.03
Pre-market−0.02 (−1.90%)
At close$1.05(+1.94%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions120 holders · as of Mar 31, 2026 | 31.62% | 24.60M shares | |
| Insiders6 holders · as of Jul 16, 2026 | 4.58% | 3.56M shares | |
| Otherremainder | 63.80% | 49.63M shares |
77.80M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
120 holders · 24.60M shares · 23 new positions · 53 increased · 37 reduced · 15 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.98M | 5.12% | −62.2K | May 13, 2026 |
| Vanguard Capital Management LLC | 2.86M | 3.67% | +2.86Mnew | May 15, 2026 |
| Laurion Capital Management LP | 2.65M | 3.40% | 0 | May 14, 2026 |
| Pfizer Inc | 2.41M | 3.10% | 0 | May 12, 2026 |
| Acorn Capital Advisors, LLC | 1.76M | 2.27% | −200.0K | May 15, 2026 |
| Geode Capital Management, LLC | 1.60M | 2.06% | +76.6K | May 15, 2026 |
| Franklin Resources Inc | 1.21M | 1.55% | 0 | May 13, 2026 |
| State Street Corp | 1.19M | 1.53% | −4.7K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.80% | 3.84M | 13G | Apr 23, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 14, 2026 | Mani Mohindrudirector, officer: Chief Executive Officer | Purchase · 2 lots | 68,728 | $1.39 | 93,431 |
| Jul 14, 2026 | Gary W. Pacedirector | Purchase · 2 lots | 1,374,570 | $1.39 | 2,730,946 |
| Jun 18, 2026 | Gary W. Pacedirector | Purchase | 30,000 | $1.22 | 1,356,376 |
| Jun 18, 2026 | Mani Mohindrudirector, officer: Chief Executive Officer | Purchase | 24,703 | $1.21 | 24,703 |
CongressHouse and Senate disclosures
Not reported.